These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
732 related articles for article (PubMed ID: 32098504)
1. Single-Cell Reconstruction of Progression Trajectory Reveals Intervention Principles in Pathological Cardiac Hypertrophy. Ren Z; Yu P; Li D; Li Z; Liao Y; Wang Y; Zhou B; Wang L Circulation; 2020 May; 141(21):1704-1719. PubMed ID: 32098504 [TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling of hypertrophic cardiomyocytes identifies new players in pathological remodelling. Vigil-Garcia M; Demkes CJ; Eding JEC; Versteeg D; de Ruiter H; Perini I; Kooijman L; Gladka MM; Asselbergs FW; Vink A; Harakalova M; Bossu A; van Veen TAB; Boogerd CJ; van Rooij E Cardiovasc Res; 2021 May; 117(6):1532-1545. PubMed ID: 32717063 [TBL] [Abstract][Full Text] [Related]
3. Adapter molecule DOC-2 is differentially expressed in pressure and volume overload hypertrophy and inhibits collagen synthesis in cardiac fibroblasts. Kumbar DH; VanBergen A; Ocampo C; Muangmingsuk S; Griffin AJ; Gupta M J Appl Physiol (1985); 2007 May; 102(5):2024-32. PubMed ID: 17255372 [TBL] [Abstract][Full Text] [Related]
4. Single-cell insights: pioneering an integrated atlas of chromatin accessibility and transcriptomic landscapes in diabetic cardiomyopathy. Su Q; Huang W; Huang Y; Dai R; Chang C; Li QY; Liu H; Li Z; Zhao Y; Wu Q; Pan DG Cardiovasc Diabetol; 2024 Apr; 23(1):139. PubMed ID: 38664790 [TBL] [Abstract][Full Text] [Related]
5. Vinpocetine Attenuates Pathological Cardiac Remodeling by Inhibiting Cardiac Hypertrophy and Fibrosis. Wu MP; Zhang YS; Xu X; Zhou Q; Li JD; Yan C Cardiovasc Drugs Ther; 2017 Apr; 31(2):157-166. PubMed ID: 28321644 [TBL] [Abstract][Full Text] [Related]
6. A Novel Role of Cyclic Nucleotide Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction. Chen S; Zhang Y; Lighthouse JK; Mickelsen DM; Wu J; Yao P; Small EM; Yan C Circulation; 2020 Jan; 141(3):217-233. PubMed ID: 31801360 [TBL] [Abstract][Full Text] [Related]
7. ATF3-dependent cross-talk between cardiomyocytes and macrophages promotes cardiac maladaptive remodeling. Koren L; Alishekevitz D; Elhanani O; Nevelsky A; Hai T; Kehat I; Shaked Y; Aronheim A Int J Cardiol; 2015 Nov; 198():232-40. PubMed ID: 26201690 [TBL] [Abstract][Full Text] [Related]
8. Lansoprazole alleviates pressure overload-induced cardiac hypertrophy and heart failure in mice by blocking the activation of β-catenin. Lin H; Li Y; Zhu H; Wang Q; Chen Z; Chen L; Zhu Y; Zheng C; Wang Y; Liao W; Bin J; Kitakaze M; Liao Y Cardiovasc Res; 2020 Jan; 116(1):101-113. PubMed ID: 30689763 [TBL] [Abstract][Full Text] [Related]
9. Ginseng reverses established cardiomyocyte hypertrophy and postmyocardial infarction-induced hypertrophy and heart failure. Moey M; Gan XT; Huang CX; Rajapurohitam V; Martínez-Abundis E; Lui EM; Karmazyn M Circ Heart Fail; 2012 Jul; 5(4):504-14. PubMed ID: 22576957 [TBL] [Abstract][Full Text] [Related]
10. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure. Xu N; Guan S; Chen Z; Yu Y; Xie J; Pan FY; Zhao NW; Liu L; Yang ZZ; Gao X; Xu B; Li CJ J Pathol; 2015 Apr; 235(5):672-85. PubMed ID: 25385233 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic Therapy for the Treatment of Hypertension-Induced Cardiac Hypertrophy and Fibrosis. Watson CJ; Horgan S; Neary R; Glezeva N; Tea I; Corrigan N; McDonald K; Ledwidge M; Baugh J J Cardiovasc Pharmacol Ther; 2016 Jan; 21(1):127-37. PubMed ID: 26130616 [TBL] [Abstract][Full Text] [Related]
12. Endothelial S1pr1 regulates pressure overload-induced cardiac remodelling through AKT-eNOS pathway. Liu X; Wu J; Zhu C; Liu J; Chen X; Zhuang T; Kuang Y; Wang Y; Hu H; Yu P; Fan H; Zhang Y; Liu Z; Zhang L J Cell Mol Med; 2020 Jan; 24(2):2013-2026. PubMed ID: 31854513 [TBL] [Abstract][Full Text] [Related]
13. Repurposing an anti-cancer agent for the treatment of hypertrophic heart disease. Dukinfield M; Maniati E; Reynolds LE; Aubdool A; Baliga RS; D'Amico G; Maiques O; Wang J; Bedi KC; Margulies KB; Sanz-Moreno V; Hobbs A; Hodivala-Dilke K J Pathol; 2019 Dec; 249(4):523-535. PubMed ID: 31424556 [TBL] [Abstract][Full Text] [Related]
14. The cardiac maladaptive ATF3-dependent cross-talk between cardiomyocytes and macrophages is mediated by the IFNγ-CXCL10-CXCR3 axis. Koren L; Barash U; Zohar Y; Karin N; Aronheim A Int J Cardiol; 2017 Feb; 228():394-400. PubMed ID: 27870968 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic Inhibition of Wang Y; Zhang M; Wang R; Lin J; Ma Q; Guo H; Huang H; Liang Z; Cao Y; Zhang X; Lu YW; Liu J; Xiao F; Yan H; Dimitrova N; Huang ZP; Mably JD; Pu WT; Wang DZ Circ Res; 2024 Jul; 135(3):434-449. PubMed ID: 38864216 [TBL] [Abstract][Full Text] [Related]
17. STEAP3 (Six-Transmembrane Epithelial Antigen of Prostate 3) Inhibits Pathological Cardiac Hypertrophy. Li PL; Liu H; Chen GP; Li L; Shi HJ; Nie HY; Liu Z; Hu YF; Yang J; Zhang P; Zhang XJ; She ZG; Li H; Huang Z; Zhu L Hypertension; 2020 Oct; 76(4):1219-1230. PubMed ID: 32862709 [TBL] [Abstract][Full Text] [Related]
18. Fibroblast GATA-4 and GATA-6 promote myocardial adaptation to pressure overload by enhancing cardiac angiogenesis. Dittrich GM; Froese N; Wang X; Kroeger H; Wang H; Szaroszyk M; Malek-Mohammadi M; Cordero J; Keles M; Korf-Klingebiel M; Wollert KC; Geffers R; Mayr M; Conway SJ; Dobreva G; Bauersachs J; Heineke J Basic Res Cardiol; 2021 Apr; 116(1):26. PubMed ID: 33876316 [TBL] [Abstract][Full Text] [Related]